Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Medincell

Medincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3
From Medincell
Via Business Wire
Medincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241
From Medincell
Via Business Wire
Medincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®
From Medincell
Via Business Wire
Medincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia
From Medincell
Via Business Wire
Medincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)
From Medincell
Via Business Wire
Medincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline
From Medincell
Via Business Wire
Medincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress
From Medincell
Via Business Wire
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
From Medincell
Via Business Wire
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
From Medincell
Via Business Wire
MedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)
From MedinCell
Via Business Wire
MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)
From MedinCell
Via Business Wire
MedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)
From MedinCell
Via Business Wire
US Biopharma Financial & IR Strategy Veteran Dr Grace Kim joins MedinCell
From MedinCell
Via Business Wire
MedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement
From MedinCell
Via Business Wire
MedinCell’s Partner Teva Announces Successful Launch of UZEDY™
From MedinCell
Via Business Wire
MedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)
From MedinCell
Via Business Wire
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
From MedinCell
Via Business Wire
MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company
From MedinCell
Via Business Wire
Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK)
From MedinCell
Via Business Wire
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
From MedinCell
Via Business Wire
Additional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive
From MedinCell
Via Business Wire
France : EIB and MedinCell Sign a New €40 Million Loan Agreement to Support Development of Innovative Treatments
From MedinCell
Via Business Wire
MedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement
From MedinCell
Via Business Wire
MedinCell’s Partner Teva Today Announced Refiling for Approval of mdc-IRM and Confirmed Planned Launch in the U.S. in H1 2023
From MedinCell
Via Business Wire
MedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission
From MedinCell
Via Business Wire
MedinCell Secures Additional 20 Million Euros Financing With the European Investment Bank (EIB)
From MedinCell
Via Business Wire
Phase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using MedinCell’s Technology
From MedinCell
Via Business Wire
An Impact Company Committed to Improving the Health of Patients Worldwide, MedinCell Publishes Its 2021-2022 ESG Annual Report
From MedinCell
Via Business Wire
MedinCell’s partner Teva confirms expectation for approval and commercialization in the US in H1 2023 for mdc-IRM/TEV46000
From MedinCell
Via Business Wire
MedinCell: US Pharma Development Expert Richard Malamut, MD Becomes Chief Medical Officer
From MedinCell
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
Copyright © 1995-2016 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.